t.ibarra

TL2 · Izmir

Contributes reviews on supplier material. Based in Izmir.

Joined 30 November 2024 · last posted 4h

83 posts, newest first. Showing up to 150.

What a reversed-phase purity number actually is Replied, post #102 · Analytics › HPLC & UHPLC · 28 Jul 2026 · 0 likes Everything in post #100 holds. The case it does not cover is the one I have. Reversed-phase separates on hydrophobicity. A peptide is retained on a non-polar stationary…
Micro-titration: a disputed topic, argued properly Replied, post #110 · Practice › Dosing & titration · 24 Jul 2026 · 0 likes Micro-titration is one of those subjects where the general answer and the answer for a specific case diverge, and the thread will go in circles until someone says which…
Prior authorisation: what the criteria usually require — a second dataset Replied, post #52 · Access › Insurance & coverage · 21 Jul 2026 · 4 likes Small correction to my own earlier position on Prior authorisation. I had the units the wrong way round, which changes the conclusion by an order of magnitude and…
Solubility limits and what a cloudy solution is telling you Replied, post #15 · Pharmacology › Formulation chemistry · 16 Jul 2026 · 0 likes Marking my place. If it changes for me I will come back and say so.
Primary endpoint hierarchies and why order matters — one year on Replied, post #47 · Evidence › Trials · 15 Jul 2026 · 0 likes Practical answer on Primary endpoint hierarchies, since the theoretical one is upthread: do the simplest check first, write down the result, and only then decide…
What I would want from a home test that does not exist yet — what changed since Replied, post #92 · Analytics › Home & field testing · 13 Jul 2026 · 10 likes Why third-party testing is stronger: a home test run by the person who made the compound is a self-selected result. The test run by a neutral third party removes…
Follow-up: How compounding permissions changed when supply normalised Replied, post #13 · Sourcing › Regulatory · 12 Jul 2026 · 0 likes Where a claim about legality is made here, the useful follow-up is which instrument it rests on. Most such claims turn out to rest on a forum post. I looked this up…
Pooling trials with different estimands Replied, post #37 · Evidence › Meta-analyses · 20 Jun 2026 · 7 likes Quietly grateful for the plain phrasing. Not every thread gets that.
I joined for one answer and stayed for a year — what changed my mind Replied, post #19 · Start Here › Welcome · 12 Jun 2026 · 3 likes Nothing here requires expertise. The experienced members here got that way by posting questions, not by knowing the answer before they showed up. If you know something…
Alcohol: what is documented and what is folklore Replied, post #43 · Practice › Interactions · 5 Jun 2026 · 20 likes Adding thanks rather than a view. I do not have a view worth the space.
Comparing documentation quality across the directory, tabulated Replied, post #4 · Sourcing › Vendor reports · 31 May 2026 · 7 likes One caution on comparing documentation quality: everything above assumes the underlying documentation is what it claims to be. That assumption is doing real work and is…
Journal club: STEP 1 and the treatment-policy estimand — does this still hold? Replied, post #28 · Evidence › Journal club · 27 May 2026 · 7 likes Answering the question post #26 raises rather than the one it answers. The most common failure mode is spending fifty minutes on the effect size and ten on the…
A single out-of-range value on an otherwise normal panel Replied, post #45 · Clinical › Bloodwork · 11 May 2026 · 0 likes The arithmetic in post #44 is right; the assumption feeding it is the part to check. Keeping your own results in a single table with dates is more useful than any…
Request: show the solution author in the topic list — what changed since Replied, post #38 · Meta › Feature requests · 2 May 2026 · 0 likes Reading back through, this was answered upthread and I missed it. My fault.
Transporting a vial for a weekend away — a second dataset Replied, post #42 · Practice › Storage & stability · 2 May 2026 · 28 likes Visible particulate is a strong signal in the other direction: it is a reason to stop and ask rather than to filter and proceed.
List price versus negotiated price versus what you pay Replied, post #105 · Access › Pricing · 17 Apr 2026 · 0 likes Practical note on list price versus negotiated price: write down what you expect before you look. The number of times I have found what I went looking for is higher…
Comparing my trajectory with the trial curves, carefully — a second dataset Replied, post #32 · Outcomes › Progress reports · 16 Apr 2026 · 13 likes Right — I had this wrong and I am glad to have read it before it mattered.
Spike-and-recover accuracy for a peptide assay Replied, post #44 · Analytics › Method validation · 8 Apr 2026 · 7 likes Practical note on spike-and-recover accuracy: write down what you expect before you look. The number of times I have found what I went looking for is higher than chance…
Common supplements people ask about, assessed one at a time — a second dataset Replied, post #77 · Practice › Interactions · 30 Mar 2026 · 17 likes Post #75 and I disagree about the size of the effect, not about the direction. Mechanistic reasoning about interactions has a poor predictive record. It is a good way…
Foaming during reconstitution and whether it matters — the long version Replied, post #66 · Practice › Reconstitution · 17 Mar 2026 · 1 like Post #63 is the version of this I will quote in future. One addition. I would call the community position on Foaming during reconstitution likely rather than…
The lowest dose that does anything: is that a real question? Replied, post #66 · Practice › Dosing & titration · 5 Mar 2026 · 1 like Steady state means the plasma concentration is stable from dose to dose. That happens around 4 to 5 half-lives. Before that, the concentration is rising with each dose.…
Packaging that arrived damaged: documenting it properly — a second dataset Replied, post #48 · Sourcing › Logistics · 2 Mar 2026 · 22 likes Documentation after arrival: photograph the parcel and its contents on arrival. If something later turns out wrong (damage, loss, wrong item) you have evidence of the…
An ABAB design with a data table and honest limitations — a second dataset Replied, post #14 · Research Methods › N-of-1 designs · 25 Feb 2026 · 5 likes Blinding yourself is harder than it sounds and is not impossible. Somebody else preparing labelled containers is the usual approach and it requires a second person you…
What a good consultation looks like from the other side Replied, post #19 · Clinical › Prescriber conversations · 24 Feb 2026 · 7 likes Post #18 put the caveat in the right place and I want to underline it. A question phrased as "what would you want to see before considering X" is answerable and is not…
Oral semaglutide bioavailability and its variability between people Replied, post #36 · Compounds › Oral incretins · 20 Feb 2026 · 3 likes Missed doses behave differently for a daily oral than for a weekly injection. With a short interval you are near a trough rather than perturbing a slowly moving…
Run-in periods and the population they select Replied, post #69 · Evidence › Trials · 19 Feb 2026 · 7 likes The arithmetic in post #68 is right; the assumption feeding it is the part to check. A treatment-policy estimand asks what happens to people assigned to a strategy,…
Older adults, sarcopenia risk, and the trade-off nobody quantifies Replied, post #103 · Clinical › Special populations · 17 Feb 2026 · 21 likes This is the sort of exchange that makes the archive worth searching.
Reading SURMOUNT-1 without the press release — one year on Replied, post #48 · Compounds › Tirzepatide · 17 Feb 2026 · 6 likes On storage: published stability data covers the licensed formulation at its licensed concentration. A research preparation reconstituted at home in a different diluent…
[2026 update] A rising related-substance total over six months: degradation or method… Replied, post #33 · Analytics › Impurities & related substances · 14 Feb 2026 · 14 likes Building on post #31 rather than restating it. Distinguishing three things in the rising related-substance discussion that keep getting used interchangeably: the…
Seven-day rolling means and why weekly readings mislead — one year on Replied, post #35 · Outcomes › Progress reports · 11 Feb 2026 · 5 likes The best progress reports here read as records rather than as arguments, and that difference is visible within a sentence. I have no interest in any supplier named above.
A supplier who responds to a discrepancy with silence — what changed since Replied, post #3 · Sourcing › Red flags · 5 Feb 2026 · 0 likes Worth separating two things that the opening post runs together. Second-hand on supplier, so weight it accordingly — someone whose method I trust told me this and I…
Pharmacy supply in the UK and the questions you will be asked Replied, post #29 · Regional › UK & Ireland · 3 Feb 2026 · 1 like The version of pharmacy supply that circulates here is a simplification of a simplification. It is not wrong, but it has lost the conditions under which it holds, and…
Revisiting: A page that has drifted out of date and needs a maintainer Replied, post #60 · Documentation › Wiki requests · 29 Jan 2026 · 9 likes Grateful for the specificity. Vague answers to this question are what sent me looking.
Follow-up: Reconciling a label claim with a content assay Replied, post #3 · Analytics › COA interpretation · 20 Jan 2026 · 4 likes The distinction between release testing and characterisation is one industrial documents make and retail ones usually do not. It is the difference between "we tested…
Waist circumference technique and its repeatability Replied, post #28 · Outcomes › Progress reports · 18 Dec 2025 · 13 likes Circumference measurements at marked sites are cheap, reproducible within a person, and more informative than they get credit for. That holds under the stated…
Why a compound being unapproved is not the same as being illegal to possess Replied, post #38 · Sourcing › Regulatory · 5 Dec 2025 · 14 likes Approval versus licensing: a compound can be approved for a specific indication in one country and not approved at all in another. Tracking jurisdictional approval is…
EU-wide position versus national implementation — what changed since Replied, post #6 · Regional › European Union · 31 Oct 2025 · 0 likes Taking post #5 at face value and following it one step further. I disagree with the framing of eu-wide position versus national implementation above, and I think it is…
What I would record differently if I started again — the long version Replied, post #14 · Outcomes › Progress reports · 24 Oct 2025 · 15 likes The best progress reports here read as records rather than as arguments, and that difference is visible within a sentence. That much is documented. The rest is how I…
Specification in the result column: why that is a meaningful error Replied, post #62 · Analytics › COA interpretation · 23 Oct 2025 · 0 likes I read post #60 twice before replying, because I had assumed the opposite. The distinction between release testing and characterisation is one industrial documents make…
A parcel that arrived warm: a decision process, not a verdict Replied, post #73 · Practice › Storage & stability · 8 Oct 2025 · 26 likes Building on post #72 rather than restating it. Temperature excursions in transit are common and are not all equal. A few hours warm is a different event from three days…
Asking about a compound your prescriber has not heard of Replied, post #139 · Clinical › Prescriber conversations · 27 Aug 2025 · 0 likes If you have been doing something the prescriber does not know about, saying so is more useful than not. Clinicians here consistently say they would rather know. I have…
Documentation that appears only after payment Replied, post #11 · Sourcing › Red flags · 25 Aug 2025 · 0 likes Building on post #10 rather than restating it. Careful with the language on documentation. "Not detected" and "not present" are different findings and the first is a…
Are there stupid questions here? A staff answer, at length Replied, post #40 · Start Here › Welcome · 4 Aug 2025 · 3 likes You do not need to introduce yourself before asking a question, and nobody will think worse of you for arriving with one. The introductions subcategory exists for…
Coming back to: Semaglutide half-life: where the 165 to 184 hour figure comes from Replied, post #89 · Compounds › Semaglutide · 27 Jul 2025 · 23 likes The useful distinction on Semaglutide half-life is between what was measured and what was inferred from it. Both end up in the same sentence and only one of them has…
Comparators chosen for regulatory reasons rather than clinical ones — one year on Replied, post #86 · Evidence › Trials · 24 Jul 2025 · 9 likes I have no financial interest in anything named in this thread and I want to say so before I comment on Comparators chosen for regulatory reasons, because it is the sort…
Interpreting a composition change that is within the error bars Replied, post #19 · Outcomes › Body composition · 21 Jul 2025 · 8 likes The claim about interpreting a composition change upthread is stronger than its source supports. I have read the source. The source says "associated with" and the post…
Coming back to: Amylin analogue mechanism: satiety signalling separate from GLP-1 Replied, post #16 · Compounds › Cagrilintide & amylin analogues · 19 Jul 2025 · 0 likes Taking post #15 at face value and following it one step further. Small methodological point on Amylin analogue mechanism: repeating a measurement is cheap and resolves…
Coming back to: The SOUL trial and oral semaglutide cardiovascular outcomes Replied, post #19 · Compounds › Oral incretins · 19 Jul 2025 · 0 likes Trial adherence in an oral trial with strict administration requirements is genuinely worse than trial-published data often suggests. That is why the exposure…
A field-by-field walk through a certificate of analysis Replied, post #20 · Analytics › COA interpretation · 14 Jul 2025 · 2 likes Appreciated. The plain phrasing does more work here than a longer post would.
Coming back to: What published stability data actually covers, and what it does not Replied, post #62 · Practice › Storage & stability · 13 Jun 2025 · 7 likes Post #59 is the version of this I will quote in future. One addition. Visible particulate is a strong signal in the other direction: it is a reason to stop and ask…
Tirzepatide in type 2 diabetes: the SURPASS programme, summarised honestly Replied, post #106 · Compounds › Tirzepatide · 9 Jun 2025 · 13 likes Answering the question post #104 raises rather than the one it answers. Reframing tirzepatide in type 2 diabetes slightly, because I think the disagreement is about the…
Half-life, steady state, and accumulation worked through Replied, post #69 · Pharmacology › Pharmacokinetics · 5 Jun 2025 · 0 likes Renal clearance: these compounds are cleared partly via the kidney. In severe renal impairment, clearance is slowed and accumulation risk is higher. Dose adjustments…
DXA precision and the least significant change for lean mass — the long version Replied, post #76 · Outcomes › Body composition · 21 May 2025 · 5 likes Confirming post #73 from a second method, which matters more than confirming it from a second person. The most useful protocol is the one you will actually repeat…
Validating a calculator against hand arithmetic — what changed since Replied, post #48 · Data & Tools › Calculators · 4 May 2025 · 2 likes On post #46 — agreed on the reasoning, with one qualification. Reconstitution calculator: enter vial mass, final volume target, and the calculator tells you…
Follow-up: Requesting a page: what makes a good request Replied, post #27 · Documentation › Wiki requests · 28 Apr 2025 · 5 likes Picking up post #24: that is the part I would want checked first. A calculator request and a document request are different things, and a calculator without a document…
Hepatic steatosis: what the MASH trial evidence supports Replied, post #25 · Clinical › Comorbidities · 23 Apr 2025 · 27 likes I had written a reply contradicting post #24 and deleted it. Here is what survived. Hepatic steatosis is a good example of a question where the honest answer is boring…
Second pass at: Reading a combination trial: attributing effect to components Replied, post #8 · Compounds › Cagrilintide & amylin analogues · 21 Apr 2025 · 0 likes The interest in combining it with semaglutide is that two different satiety mechanisms might add. Whether they do, and by how much, is exactly what the combination…
Carryover and the ghost peak from last week's standard Replied, post #45 · Analytics › HPLC & UHPLC · 7 Apr 2025 · 27 likes Peaks that do not elute do not appear in the area percentage. Aggregates and strongly retained species can be entirely invisible to a standard method, which is a…
Ipamorelin selectivity claims and where they came from — a second dataset Started this topic · Compounds › Secretagogues & GH axis · 6 Apr 2025 · 24 likes Posting this under the heading it deserves: Ipamorelin selectivity claims and where they came from — a second dataset Everything below is what sits behind that. Posting…
One lot is one lot: when a report becomes a pattern — the long version Replied, post #17 · Sourcing › Vendor reports · 15 Mar 2025 · 25 likes Where you submitted more than one vial from a consignment, say so. Intra-consignment comparison is one of the more useful things an individual can contribute. That…
Follow-up: Open-label extensions: what survives and what does not Replied, post #9 · Evidence › Trials · 10 Mar 2025 · 0 likes I had written a reply contradicting post #7 and deleted it. Here is what survived. One more thing on Open-label extensions that took me far too long to see: the two…
How compounding permissions changed when supply normalised Replied, post #28 · Sourcing › Regulatory · 9 Mar 2025 · 28 likes The reason compounding permissions is hard to answer is that the obvious measurement and the relevant quantity are not the same thing, and substituting one for the…
Random versus fixed effects: choosing rather than defaulting — a second dataset Replied, post #97 · Evidence › Meta-analyses · 12 Feb 2025 · 4 likes The number people quote for Random versus fixed effects is a central estimate presented without its interval, and the interval is wide enough that the estimate is…
Ipamorelin selectivity claims and where they came from Replied, post #5 · Compounds › Secretagogues & GH axis · 7 Jan 2025 · 28 likes I read post #3 twice before replying, because I had assumed the opposite. A request rather than an answer: could whoever has the primary source for ipamorelin…
Coming back to: Preparing for an appointment: one page, three questions Replied, post #136 · Clinical › Prescriber conversations · 1 Jan 2025 · 19 likes Bringing a record of symptoms with dates and severities makes an assessment materially easier and is the single most useful preparation. That much is documented. The…
Body image changing more slowly than the body Replied, post #131 · Wellbeing › Mental health · 25 Dec 2024 · 19 likes Relationship with food changing is one of the most commonly described experiences here and is discussed far less than the physical effects.
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #65 · Evidence › Journal club · 19 Dec 2024 · 6 likes I had written a reply contradicting post #61 and deleted it. Here is what survived. FLOW (N Engl J Med 2024): Semaglutide renal outcomes in type 2 diabetes and chronic…
A promotion I argued against, and why I lost Replied, post #22 · Documentation › Doc review · 6 Dec 2024 · 0 likes I read post #20 twice before replying, because I had assumed the opposite. Careful with the language on promotion. "Not detected" and "not present" are different…
Meeting a protein target on a suppressed appetite — does this still hold? Replied, post #21 · Nutrition & Training › Protein & intake · 25 Nov 2024 · 23 likes Maintenance changes the calculation and almost nobody revisits their target when they get there. I am not the right person to answer the follow-up to this.
Washout with a one-week half-life: the arithmetic Replied, post #9 · Research Methods › N-of-1 designs · 23 Nov 2024 · 0 likes Agreed on washout, with one qualification that I think matters. The reasoning holds for the case as described. Change the starting assumption and it does not, and the…
Second pass at: A field-by-field walk through a certificate of analysis Replied, post #113 · Analytics › COA interpretation · 11 Nov 2024 · 12 likes Amino acid analysis gives content: it hydrolyses the peptide and quantifies the residues. It measures the peptide content independent of chromatographic purity. Very…
Revisiting: Moderation log format change Replied, post #15 · Meta › Announcements · 3 Nov 2024 · 6 likes Appreciated. The plain phrasing does more work here than a longer post would.
Follow-up: Dead volume across syringe and needle combinations Replied, post #51 · Devices › Syringes & needles · 18 Oct 2024 · 0 likes Taking post #48 at face value and following it one step further. Fixed-needle insulin syringes have the least dead volume of any common configuration. At small doses…
[2026 update] Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #4 · Evidence › Journal club · 6 Oct 2024 · 0 likes SOUL (N Engl J Med 2025): Oral semaglutide cardiovascular outcomes. Extends the cardiovascular evidence to the oral formulation. Note that oral bioavailability is lower…
Splitting a vial for two laboratories: how to do it without ruining both — what changed… Replied, post #34 · Sourcing › Independent verification · 3 Sep 2024 · 3 likes It does not extend to lots nobody has seen, it is not a recommendation, and it says nothing about anything other than what was measured.
Follow-up: A site rotation scheme that is easy enough to actually follow Replied, post #4 · Practice › Administration · 1 Sep 2024 · 17 likes Bleeding at the site is common and unremarkable at these needle gauges. Persistent bruising in the same area repeatedly is worth a change of technique or of site rather…
Journal club: SURPASS-2 and the semaglutide 1 mg comparator Replied, post #28 · Evidence › Journal club · 28 Aug 2024 · 7 likes Where I part company with post #26, and it is a narrow parting. What I want from this SURPASS-2 thread is the list of things that would need to be true for the claim to…
How to ask for a dose change without antagonising anyone Replied, post #19 · Clinical › Prescriber conversations · 27 Aug 2024 · 19 likes A question phrased as "what would you want to see before considering X" is answerable and is not a request for X. Anyone with a larger sample, please post it.
Signs of dehydration worth acting on Replied, post #6 · Safety › Adverse events · 17 Aug 2024 · 15 likes A note on scope: what I am saying about signs of dehydration worth acting applies to the case in the first post and I would not extend it further without checking.
Promotion criteria, and the one that stops most nominations Replied, post #35 · Documentation › Doc review · 10 Aug 2024 · 3 likes Reviewing your own nomination is fine and is not sufficient. Somebody else has to read it for the process to mean anything. Not disagreeing with anyone above, just…
Cold packs, phase-change material, and what survives ten days Replied, post #56 · Sourcing › Logistics · 30 Jun 2024 · 0 likes Trying to state the cold packs position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread passes that test.
The mass-error checker and its intended scope Replied, post #32 · Data & Tools › Calculators · 6 Jun 2024 · 3 likes I had written a reply contradicting post #31 and deleted it. Here is what survived. Unit-conversion tools are only as good as the assumption they make about the…
Assessing a warm arrival: the decision process — one year on Replied, post #113 · Sourcing › Logistics · 1 Jun 2024 · 2 likes Trying to state the Assessing a warm arrival position in a way that someone who disagrees would recognise as fair, because I do not think the version in this thread…